Fact Sheets

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Overview and Opportunity

October 2016

Bremelanotide is in Phase 3 development as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide, a first-in-class melanocortin receptor 4 agonist, is the only as needed pharmaceutical agent for HSDD to successfully complete and meet the objectives of a robust and well-designed phase 2B randomized and controlled clinical trial.

MC4r Agonist for the Treatment of Obesity and Diabetes

January 2016

PL-8905 is the lead preclinical candidate being developed by Palatin Technologies (Palatin) as a treatment for obesity, diabetes and related metabolic syndromes.

PL-3994 for the Treatment of Heart Failure

January 2016

Palatin Technologies is initiating its Phase II development plan of PL-3994, the Company’s lead product candidate for the treatment of heart failure.

MC1r Agonist for the Treatment of Inflammatory, Dermatologic and Ocular Indications

January 2016

PL-8177, a highly selective melanocortin receptor-1 (MC1r) agonist, is the lead preclinical candidate under development by Palatin Technologies (Palatin) for treatment of inflammatory and autoimmune indications.